Two Sigma Investments LP Purchases New Position in Rani Therapeutics Holdings, Inc. (NASDAQ:RANI)

Two Sigma Investments LP purchased a new stake in shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 291,381 shares of the company’s stock, valued at approximately $399,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in RANI. Janney Montgomery Scott LLC acquired a new stake in Rani Therapeutics during the 4th quarter worth approximately $37,000. Virtu Financial LLC acquired a new stake in Rani Therapeutics during the 4th quarter worth approximately $62,000. Insigneo Advisory Services LLC acquired a new stake in Rani Therapeutics during the 4th quarter worth approximately $65,000. Finally, Takeda Pharmaceutical Co. Ltd. acquired a new stake in Rani Therapeutics during the 4th quarter worth approximately $278,000. 30.19% of the stock is owned by institutional investors.

Rani Therapeutics Stock Up 1.5%

Shares of NASDAQ RANI opened at $0.58 on Wednesday. The company has a market capitalization of $33.51 million, a P/E ratio of -0.55 and a beta of 0.25. Rani Therapeutics Holdings, Inc. has a 52-week low of $0.46 and a 52-week high of $4.45. The company has a debt-to-equity ratio of 2.34, a quick ratio of 1.60 and a current ratio of 1.60. The company’s 50 day moving average price is $0.88 and its 200-day moving average price is $1.31.

Rani Therapeutics (NASDAQ:RANI) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.22) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.22). The firm had revenue of $0.20 million during the quarter. Equities analysts forecast that Rani Therapeutics Holdings, Inc. will post -1.01 earnings per share for the current year.

Analyst Ratings Changes

RANI has been the topic of several recent research reports. Canaccord Genuity Group reiterated a “buy” rating and set a $9.00 target price on shares of Rani Therapeutics in a research report on Wednesday, February 26th. HC Wainwright reiterated a “buy” rating and set a $9.00 target price on shares of Rani Therapeutics in a research report on Thursday, April 3rd. Finally, Oppenheimer cut their target price on shares of Rani Therapeutics from $14.00 to $4.00 and set an “outperform” rating on the stock in a research report on Friday, May 16th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Rani Therapeutics presently has a consensus rating of “Buy” and an average target price of $9.40.

About Rani Therapeutics

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.